// App-Quantinova.ai

3763 : Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial

Researchers

Presenter

  • Dong-Wook Kim

Principal Investigators

  • John F. DiPersio

  • Daniel Deangelo

  • Elisabetta Abruzzese

  • Delphine Rea

  • Michele Baccarani

  • Martin C Muller

  • Carlo Gambacorti-Passerini

  • Stephane Wong

  • Stephanie Lustgarten

  • Victor M. Rivera

  • Maritza Lienlaf

  • Tim Clackson

  • Christopher D. Turner

  • Frank G Haluska

  • Francois Guilhot

  • Michael W. Deininger

  • Timothy P. Hughes

  • John M Goldman

  • Neil Shah

  • Hagop M. Kantarjian

  • Jorge E. Cortes

  • Philipp le Coutre

  • Ronald Paquette

  • Charles Chuah

  • Franck E. Nicolini

  • Jane Apperley

  • H. Jean Khoury

  • Moshe Talpaz

Medical Centers

  • Urologische Klinik Universitatsmedizin Mannheim, Mannheim, Germany

  • Ematologia, Ospedale S. Eugenio, Universita Tor Vergata, Rome, Italy

  • Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy

  • University of Milano-Bicocca, Monza, Italy

  • Medizinische Klinik m.S., Hamatologie, Onkologie und Tumorimmunologie, Charite, Universitatsmedizin Berlin, Berlin, Germany

  • Department of Haematology, SA Pathology and Royal Adelaide Hospital, Adelaide, Australia

  • Department of Hematology, Singapore General Hospital, Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • Department of Obstetrics and Gynecology, Universitatsklinikum Halle, Halle, Germany

  • H. Lee Moffitt Cancer Center & Imperial College, Department of Haematology, Hammersmith Hospital, London, United Kingdom

  • Division of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea,

  • Service des Maladies du Sang, Hopital Saint-Louis, Paris, France

  • Department of Histopathology, Imperial College London, London, United Kingdom

  • CHU Poitiers, Poitiers, France

Locations

  • Republic of South Korea

  • Italy

  • Singapore

  • Germany

  • United Kingdom

  • Australia

  • France

Companies

  • ARIAD Pharmaceutical

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

Drug/Treatment

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved